At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09939 KINTOR PHARMA-B
Trading 06-01 13:36:03
2.510
+0.210
+9.13%
High2.540
Low2.340
Vol1.53M
Open2.300
D1 Closing2.300
Amplitude8.70%
Mkt Cap1.25B
Tradable Cap1.25B
Total Shares499.00M
T/O3.75M
T/O Rate0.31%
Tradable Shares499.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Pharmaceutical and Biologics Sector Navigates Growth and Adjustment, Focus on Bottoming and Recovery Turning Point
Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases
Kintor Pharma-B (09939): KX-826 Presents Phase III Trial Data for Androgenetic Alopecia and Combination Study at WCHR 2026, Receives Outstanding Poster Award
Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO
Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.